Kiniksa Pharmaceuticals International plc held its Annual Meeting of Shareholders on June 3, 2025. The re-election of Sanj K. Patel, Thomas R. Malley, and Richard S. Levy as Class I Directors was approved. The re-election of Stephen R. Biggar, G. Bradley Cole, and Barry was also approved. Additionally, the election of Felix J. Baker, M. Cantey Boyd, Tracey L. McCain, and Kimberly J. Popovits as Class III Directors was approved. The appointment of PricewaterhouseCoopers LLP as the company's UK statutory auditors and the ratification of PwC as the US independent registered public accounting firm for the fiscal year ending December 31, 2025, were both approved.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。